PE20071451A1 - DERIVADOS DE (CIS)-8-FLUORODIBENZO[b,f]PIRIDO[1,2-d]OXAZEPIN-1-AMINA COMO MODULADORES DE LOS RECEPTORES DE LA PROGESTERONA - Google Patents

DERIVADOS DE (CIS)-8-FLUORODIBENZO[b,f]PIRIDO[1,2-d]OXAZEPIN-1-AMINA COMO MODULADORES DE LOS RECEPTORES DE LA PROGESTERONA

Info

Publication number
PE20071451A1
PE20071451A1 PE2007001315A PE2007001315A PE20071451A1 PE 20071451 A1 PE20071451 A1 PE 20071451A1 PE 2007001315 A PE2007001315 A PE 2007001315A PE 2007001315 A PE2007001315 A PE 2007001315A PE 20071451 A1 PE20071451 A1 PE 20071451A1
Authority
PE
Peru
Prior art keywords
oxazepin
cis
pyrid
fluorodibenzo
modulators
Prior art date
Application number
PE2007001315A
Other languages
English (en)
Inventor
Johannes Bernardus Maria Rewinkel
Brigitte Johanna Bernita Folmer
Ollero Maria Lourdes Ollero
Hemen Ibrahim
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of PE20071451A1 publication Critical patent/PE20071451A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE (CIS)-8-FLUORODIBENZO[b,f]PIRIDO[1,2-d]OXAZEPIN-1-AMINA, DE FORMULA (I), EN DONDE R1 ES ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO POR HALOGENO; R2 ES H, HALOGENO, ALQUILO(C1-C6) Y CN; R3, R4 Y R5 SON INDEPENDIENTEMENTE H O F. SON SELECCIONADOS: (-)-(CIS)-N-(7-BROMO-8-FLUORO-1,3,4,14b-TETRAHIDRO-2H-DIBENZO[b,f]PIRIDO[1,2-d][1,4]OXAZEPIN-1-IL)-2,2,2,-TRIFLUOROACETAMIDA, (-)-(CIS)-N-(6-CLORO-7-CIANO-8,12-DIFLUORO-1,3,4,14b-1,3,4,14b-TETRAHIDRO-2H-DIBENZO[b,f]PIRIDO[1,2-d][1,4]OXAZEPIN-1-IL)ACETAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SOM MODULADORES DE LOS RECEPTORES DE PROGESTERONA, SIENDO UTILES EN EL CAMPO DE LA ANTICONCEPCION, TERAPIA DE REMPLAZO HORMONAL Y EN EL TRATAMIENTO DE TRASTORNOS GINECOLOGICOS
PE2007001315A 2006-09-27 2007-09-27 DERIVADOS DE (CIS)-8-FLUORODIBENZO[b,f]PIRIDO[1,2-d]OXAZEPIN-1-AMINA COMO MODULADORES DE LOS RECEPTORES DE LA PROGESTERONA PE20071451A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121372 2006-09-27

Publications (1)

Publication Number Publication Date
PE20071451A1 true PE20071451A1 (es) 2008-10-30

Family

ID=37813577

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001315A PE20071451A1 (es) 2006-09-27 2007-09-27 DERIVADOS DE (CIS)-8-FLUORODIBENZO[b,f]PIRIDO[1,2-d]OXAZEPIN-1-AMINA COMO MODULADORES DE LOS RECEPTORES DE LA PROGESTERONA

Country Status (27)

Country Link
EP (1) EP2066677B1 (es)
JP (1) JP2010504943A (es)
KR (1) KR20090064454A (es)
CN (1) CN101522689B (es)
AR (1) AR063018A1 (es)
AT (1) ATE478078T1 (es)
AU (1) AU2007302007B2 (es)
BR (1) BRPI0716830A2 (es)
CA (1) CA2664120A1 (es)
CL (1) CL2007002788A1 (es)
CO (1) CO6160325A2 (es)
CY (1) CY1110846T1 (es)
DE (1) DE602007008589D1 (es)
DK (1) DK2066677T3 (es)
ES (1) ES2349325T3 (es)
HR (1) HRP20100526T1 (es)
IL (1) IL197365A0 (es)
MX (1) MX2009002804A (es)
NO (1) NO20091016L (es)
NZ (1) NZ575276A (es)
PE (1) PE20071451A1 (es)
PL (1) PL2066677T3 (es)
PT (1) PT2066677E (es)
RU (1) RU2009115643A (es)
SI (1) SI2066677T1 (es)
TW (1) TW200820975A (es)
WO (1) WO2008037746A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI297685B (en) 2002-04-04 2008-06-11 Organon Nv Non-steroidal progesterone receptor modulators
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
US8063037B2 (en) 2007-05-07 2011-11-22 N. V. Organon Progesterone receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508373A (ja) * 2000-09-07 2004-03-18 バイエル・フアーマシユーチカルズ・コーポレーシヨン 環式および非環式アミジンおよびプロゲステロン受容体結合剤として使用するためのそれらを含有する医薬組成物
TWI297685B (en) * 2002-04-04 2008-06-11 Organon Nv Non-steroidal progesterone receptor modulators

Also Published As

Publication number Publication date
CA2664120A1 (en) 2008-04-03
PT2066677E (pt) 2010-11-10
JP2010504943A (ja) 2010-02-18
CL2007002788A1 (es) 2008-04-18
AR063018A1 (es) 2008-12-23
AU2007302007B2 (en) 2012-02-02
CN101522689B (zh) 2012-01-11
EP2066677B1 (en) 2010-08-18
HK1126767A1 (en) 2009-09-11
SI2066677T1 (sl) 2010-12-31
DK2066677T3 (da) 2010-11-08
AU2007302007A1 (en) 2008-04-03
RU2009115643A (ru) 2010-11-10
TW200820975A (en) 2008-05-16
CY1110846T1 (el) 2015-06-10
HRP20100526T1 (hr) 2010-11-30
EP2066677A1 (en) 2009-06-10
CO6160325A2 (es) 2010-05-20
PL2066677T3 (pl) 2011-02-28
KR20090064454A (ko) 2009-06-18
WO2008037746A1 (en) 2008-04-03
CN101522689A (zh) 2009-09-02
ATE478078T1 (de) 2010-09-15
NZ575276A (en) 2011-07-29
NO20091016L (no) 2009-03-30
IL197365A0 (en) 2009-12-24
MX2009002804A (es) 2009-03-31
BRPI0716830A2 (pt) 2013-11-05
DE602007008589D1 (de) 2010-09-30
ES2349325T3 (es) 2010-12-30

Similar Documents

Publication Publication Date Title
UA94600C2 (en) Indole sulfonamide modulators of progesterone receptors
PE20130401A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20081689A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas y su preparacion
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
PE20080997A1 (es) Compuestos n-fenilmetil-5-oxo-prolina-2-amida como moduladores de receptores p2x7
UY28150A1 (es) Agentes terapeuticos
PE20081831A1 (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
AR049706A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20141110A1 (es) Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos
NO20090760L (no) Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet
WO2007022934A3 (en) Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
AR078756A1 (es) Moduladores alostericos positivos (map)
PE20071093A1 (es) COMPUESTOS HETEROCICLICOS BICICLICOS COMO MODULADORES DEL RECEPTOR CRTh2
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
PE20141556A1 (es) Derivados de etinilo como moduladores alostericos de mglur5
SG171681A1 (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed